Special Drug Use Investigation of Nexavar (Unresectable Hepatocellular Carcinoma)
N/A
N/A
N/A
N/A
N/A
Open (Enrolling)
Both
Carcinoma, Hepatocellular
Both
Carcinoma, Hepatocellular
Trial Information
Special Drug Use Investigation of Nexavar (Unresectable Hepatocellular Carcinoma)
Inclusion Criteria:
- Patients who received Nexavar for unresectable hepatocellular carcinoma
Exclusion Criteria:
- Patients who are contraindicated based on the product label
Type of Study:
Observational
Study Design:
Observational Model: Case-Only, Time Perspective: Prospective
Outcome Measure:
Incidence of adverse drug reactions and serious adverse events in subjects who received Nexavar
Outcome Time Frame:
After Nexavar administration, up to 1 year
Safety Issue:
Yes
Principal Investigator
Bayer Study Director
Investigator Role:
Study Director
Investigator Affiliation:
Bayer
Authority:
Japan: Ministry of Health, Labor and Welfare
Study ID:
15039
NCT ID:
NCT01411436
Start Date:
May 2009
Completion Date:
January 2016
Related Keywords:
- Carcinoma, Hepatocellular
- Nexavar
- unresectable hepatocellular carcinoma
- Carcinoma
- Carcinoma, Hepatocellular
Name | Location |
|---|
